Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Exact Sciences: 4Q Earnings Snapshot

02/11/2020 | 05:12pm EST

MADISON, Wis. (AP) _ Exact Sciences Corp. (EXAS) on Tuesday reported fourth-quarter net income of $77.9 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Madison, Wisconsin-based company said it had net income of 54 cents. Losses, adjusted for pretax gains, were 37 cents per share.

The results met Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for a loss of 37 cents per share.

The molecular diagnostics company posted revenue of $295.6 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $294.4 million.

For the year, the company reported that its loss narrowed to $84 million, or 64 cents per share. Revenue was reported as $876.3 million.

Exact Sciences expects full-year revenue in the range of $1.61 billion to $1.65 billion.

Exact Sciences shares have risen 2.5% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $94.83, a rise of roughly 8% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXAS at https://www.zacks.com/ap/EXAS

Automated Insights, source Associated Press News

All news about EXACT SCIENCES CORPORATION
11/10EXACT SCIENCES : Code of Business Conduct and Ethics
PU
11/10EXACT SCIENCES : Policy Governing Director Nominations
PU
10/27EXACT SCIENCES : to buy cancer-screening firm Thrive Earlier Detection in $2.15 ..
RE
10/27EXACT SCIENCES : Infographic
PU
10/27EXACT SCIENCES : 3Q Earnings Snapshot
AQ
10/27EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
10/07PFIZER : Will Continue Helping Exact Sciences With Cologuard Promotion Through 2..
DJ
09/21EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
07/31EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
07/30EXACT SCIENCES : 2Q Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2020 1 451 M - -
Net income 2020 -379 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -48,0x
Yield 2020 -
Capitalization 18 648 M 18 648 M -
EV / Sales 2020 12,7x
EV / Sales 2021 10,1x
Nbr of Employees 4 110
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 150,43 $
Last Close Price 117,26 $
Spread / Highest target 37,3%
Spread / Average Target 28,3%
Spread / Lowest Target 19,4%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION26.80%19 169
GUARDANT HEALTH, INC.46.03%11 408
INVITAE CORPORATION215.69%8 998
BGI GENOMICS CO., LTD.88.20%8 015
ADAPTIVE BIOTECHNOLOGIES CORPORATION53.18%6 251
IOVANCE BIOTHERAPEUTICS, INC.34.94%5 479